David Nierengarten
Stock Analyst at Wedbush
(4.28)
# 350
Out of 5,174 analysts
219
Total ratings
50.83%
Success rate
15.52%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $4.29 | +156.41% | 6 | Mar 18, 2026 | |
| COGT Cogent Biosciences | Reiterates: Outperform | $55 | $34.96 | +57.32% | 5 | Mar 17, 2026 | |
| ARGX argenx SE | Reiterates: Outperform | $1,000 | $677.50 | +47.60% | 25 | Mar 9, 2026 | |
| STTK Shattuck Labs | Maintains: Outperform | $4 → $8 | $6.12 | +30.72% | 2 | Mar 6, 2026 | |
| TCRX TScan Therapeutics | Maintains: Outperform | $4 → $5 | $1.03 | +385.44% | 5 | Mar 5, 2026 | |
| APGE Apogee Therapeutics | Maintains: Outperform | $90 → $95 | $73.00 | +30.14% | 4 | Mar 3, 2026 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $57 → $65 | $23.95 | +171.40% | 4 | Feb 25, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $50 → $53 | $44.94 | +17.94% | 6 | Feb 25, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $20 | $11.10 | +80.18% | 10 | Feb 24, 2026 | |
| ABVX ABIVAX Société Anonyme | Initiates: Underperform | $110 | $110.17 | -0.15% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $88 | $59.61 | +47.63% | 5 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.28 | +157.01% | 12 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $20.21 | +53.39% | 7 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $18 | $11.36 | +58.45% | 9 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $18.16 | +65.20% | 3 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $8.72 | +186.70% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $7 | $12.81 | -45.36% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $7 | $1.13 | +519.47% | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $115 | $96.15 | +19.60% | 6 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $11.89 | +118.67% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $8.77 | +150.86% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $12.15 | -34.16% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $23.57 | -15.15% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $63.02 | -36.53% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $42.30 | +11.11% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $39.90 | +0.25% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $42.22 | +6.58% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $5.23 | +244.17% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.52 | +240.91% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $1.51 | +33,012.58% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $5.44 | +1,002.94% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $6.02 | +215.61% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $18.50 | +305.41% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.14 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.92 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.73 | - | 3 | Nov 20, 2017 |
Perspective Therapeutics
Mar 18, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.29
Upside: +156.41%
Cogent Biosciences
Mar 17, 2026
Reiterates: Outperform
Price Target: $55
Current: $34.96
Upside: +57.32%
argenx SE
Mar 9, 2026
Reiterates: Outperform
Price Target: $1,000
Current: $677.50
Upside: +47.60%
Shattuck Labs
Mar 6, 2026
Maintains: Outperform
Price Target: $4 → $8
Current: $6.12
Upside: +30.72%
TScan Therapeutics
Mar 5, 2026
Maintains: Outperform
Price Target: $4 → $5
Current: $1.03
Upside: +385.44%
Apogee Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $90 → $95
Current: $73.00
Upside: +30.14%
Beam Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $57 → $65
Current: $23.95
Upside: +171.40%
Kiniksa Pharmaceuticals International,
Feb 25, 2026
Maintains: Outperform
Price Target: $50 → $53
Current: $44.94
Upside: +17.94%
ORIC Pharmaceuticals
Feb 24, 2026
Reiterates: Outperform
Price Target: $20
Current: $11.10
Upside: +80.18%
ABIVAX Société Anonyme
Feb 24, 2026
Initiates: Underperform
Price Target: $110
Current: $110.17
Upside: -0.15%
Feb 17, 2026
Maintains: Outperform
Price Target: $110 → $88
Current: $59.61
Upside: +47.63%
Feb 10, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.28
Upside: +157.01%
Jan 15, 2026
Reiterates: Outperform
Price Target: $31
Current: $20.21
Upside: +53.39%
Jan 15, 2026
Reiterates: Neutral
Price Target: $18
Current: $11.36
Upside: +58.45%
Jan 13, 2026
Reiterates: Outperform
Price Target: $30
Current: $18.16
Upside: +65.20%
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $8.72
Upside: +186.70%
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $12.81
Upside: -45.36%
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.13
Upside: +519.47%
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $96.15
Upside: +19.60%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $11.89
Upside: +118.67%
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $8.77
Upside: +150.86%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $12.15
Upside: -34.16%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $23.57
Upside: -15.15%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $63.02
Upside: -36.53%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $42.30
Upside: +11.11%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $39.90
Upside: +0.25%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $42.22
Upside: +6.58%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $5.23
Upside: +244.17%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.52
Upside: +240.91%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $1.51
Upside: +33,012.58%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $5.44
Upside: +1,002.94%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $6.02
Upside: +215.61%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $18.50
Upside: +305.41%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.14
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.92
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $8.73
Upside: -